Compare Pure Storage (P) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pure Storage vs Tango Therapeutics Inc. — how do they compare? Pure Storage trades at $137.78 (market cap $47.15B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Pure Storage is far larger — about 12.6× Tango Therapeutics Inc.'s market cap, and Pure Storage is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 4 Days and Tango Therapeutics Inc. for 0 Days on average.
| P | TNGX | |
|---|---|---|
Market Cap | $47.15B | $3.74B |
Volume | 4,976,593 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $156.97 | $32.90 |
52-Week Low | $56.99 | $7.50 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $46.37B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Everpure (P) trades at $156.97, up 1.07% today, near its 52-week high. The stock shows strong momentum with a bullish technical signal, supported by three consecutive quarterly earnings beats. Revenue grew from $3.17B in 2025 to $4.3B in 2026, with net income more than doubling. Recent news highlights a 147% six-month surge driven by AI-driven growth targets and positive investor sentiment.
Outlook remains optimistic due to robust earnings performance and AI expansion plans, but high valuation multiples (P/E 215) and overbought technical indicators pose risks. Analyst consensus is strongly bullish with a $141.47 price target, though insider selling and competitive pressures warrant caution for new investments.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Pure Storage
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
